Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Clinical Data at the 2014 Bone Marrow Transplant Tandem Meetings

[at noodls] – -Interim Data Demonstrate 92 Percent Objective Response Rate in Ongoing Phase 1/2 Clinical Trial Evaluating ADCETRIS in Combination with Bendamustine for the Treatment of Salvage Hodgkin Lymphoma- BOTHELL, … more

View todays social media effects on SGEN

View the latest stocks trending across Twitter. Click to view dashboard

See who Seattle is hiring next, click here to view